Subject(s)
Ice , Postpartum Hemorrhage , Cesarean Section , Female , Humans , Postpartum Period , Pregnancy , Retrospective StudiesSubject(s)
Bacterial Infections/diagnosis , Endocarditis/diagnosis , Algorithms , Anti-Bacterial Agents/therapeutic use , Aortic Valve/abnormalities , Aortic Valve/surgery , Bacterial Infections/therapy , Cardiac Surgical Procedures , Combined Modality Therapy , Diagnosis, Differential , Echocardiography, Transesophageal , Endocarditis/therapy , Heart Valve Prosthesis Implantation , Humans , Inflammation Mediators/blood , Male , Platelet Aggregation Inhibitors/therapeutic use , Young AdultSubject(s)
Neuroendocrine Tumors/diagnosis , Neuroendocrine Tumors/therapy , Biopsy , Chromogranin A/blood , Diagnostic Imaging , Follow-Up Studies , Humans , Liver/pathology , Liver Neoplasms/diagnosis , Liver Neoplasms/pathology , Liver Neoplasms/secondary , Liver Neoplasms/therapy , Neoplasms, Unknown Primary/diagnosis , Neoplasms, Unknown Primary/pathology , Neoplasms, Unknown Primary/therapy , Neuroendocrine Tumors/classification , Neuroendocrine Tumors/pathology , PrognosisSubject(s)
Edema/diagnosis , Neck/pathology , Physical Exertion , Adult , Edema/etiology , Edema/pathology , Female , Humans , Lymphatic Vessels/pathology , Magnetic Resonance ImagingSubject(s)
Altitude Sickness/diagnosis , Acclimatization/physiology , Altitude Sickness/physiopathology , Altitude Sickness/therapy , Diagnosis, Differential , Emergency Medical Services , Hemodynamics/physiology , Humans , Male , Middle Aged , Oxygen/blood , Risk Factors , Sleep Apnea, Central/diagnosis , Sleep Apnea, Central/physiopathology , Sleep Apnea, Central/therapySubject(s)
Telangiectasia, Hereditary Hemorrhagic/diagnosis , Aged , Angiogenesis Inhibitors/therapeutic use , Antibodies, Monoclonal, Humanized/therapeutic use , Bevacizumab , Diagnosis, Differential , Epistaxis/etiology , Epistaxis/genetics , Epistaxis/therapy , Erythrocyte Transfusion , Gastrointestinal Hemorrhage/etiology , Gastrointestinal Hemorrhage/genetics , Gastrointestinal Hemorrhage/therapy , Hemoptysis/etiology , Hemoptysis/therapy , Hepatic Encephalopathy/diagnosis , Hepatic Encephalopathy/therapy , Humans , Intracranial Arteriovenous Malformations/diagnosis , Intracranial Arteriovenous Malformations/genetics , Liver/blood supply , Lung/blood supply , Magnetic Resonance Imaging , Male , Telangiectasia, Hereditary Hemorrhagic/genetics , Tomography, X-Ray Computed , Ultrasonography, Doppler, DuplexSubject(s)
Arthritis, Gouty/diagnosis , Arthritis, Gouty/drug therapy , Gout/diagnosis , Gout/drug therapy , Aged , Anti-Inflammatory Agents, Non-Steroidal/therapeutic use , Arthritis, Gouty/etiology , Colchicine/therapeutic use , Diagnosis, Differential , Diagnostic Imaging/methods , Gout/etiology , Gout Suppressants/therapeutic use , Humans , Kidney Transplantation , Male , Microscopy/methods , Postoperative Complications/diagnosis , Postoperative Complications/drug therapy , Postoperative Complications/etiology , Practice Guidelines as Topic , Prednisone/therapeutic use , Secondary Prevention , Synovial Fluid/chemistry , Uric Acid/analysisABSTRACT
AIMS: False aneurysms can be treated surgically or by ultrasound guided manual compression. Another method is to inject thrombin into the aneurysm under ultrasound guidance. We evaluated safety and efficacy of this approach in a multicentre registry. METHODS AND RESULTS: In 595 consecutive patients a pseudoaneurysm (593 femoral arteries, 2 brachial arteries) was diagnosed 0 to 250 days (median 3 days) after a catheter procedure. The diameter of the aneurysm ranged from 0.5x0.5x0.5 (LxWxD) to 8x11x16 cm (median 2x2x1.6 cm). 20 U to 4000 U (median 400 U) of thrombin solution were injected into the aneurysm under ultrasound guidance.The procedure was technically successful in 587/595 (99%) patients.The aneurysms were thrombosed after the first injection in 531 (89%) patients. Thirty-eight (6%) patients needed a second injection and eight (1%) patients, a third injection because residual flow in the aneurysm was visible at follow-up. In four (0.7%) additional patients the thrombosis of the aneurysms was delayed and occurred only after 24 hours to seven days. Six (1%) patients surgery was performed after successful closure of the aneurysm to remove the resulting haematoma. The overall technical success rate was 99% and clinical success was achieved in 96%.Eight (1%) other patients underwent surgery due to thrombin injection failure.Complications occurred in nine patients (1,5%). Intravascular thrombus formation, deep venous thrombosis, pulmonary embolism due to deep venous thrombosis, transient paresthesia in the leg during injection. CONCLUSIONS: Ultrasound guided thrombin injection is a safe, effective and rapid treatment of false aneurysms. Complications and recurrent pseudoaneurysms are rare.
ABSTRACT
Vascular reactivity to nitric oxide (NO) is mediated by NO-sensitive soluble guanylyl cyclase (sGC). Since a diminished activity of vascular sGC has been reported in an animal model of type 2 diabetes, the sGC activity was assayed in vitro in internal mammary artery specimens obtained during bypass surgery from patients with and without type 2 diabetes. The sensitivity of sGC to NO, which is dependent on Fe(2+)-containing heme, was measured in vitro using stimulation with diethylamine NONOate (DEA/NO). In addition, the novel cyclic guanosine monophosphate-elevating compound HMR-1766 was used to test the stimulation of the oxidized heme-Fe(3+)-containing form of sGC. Basal activity of sGC and its sensitivity to stimulation by DEA/NO and HMR-1766 were not different between control and type 2 diabetic patients: maximum stimulation by DEA/NO amounted to 475 +/- 67 and 418 +/- 59 pmol. mg(-1). min(-1) in control and type 2 diabetic patients, respectively. The maximum effects of HMR-1766 were 95 +/- 18 (control subjects) and 83 +/- 11 pmol. mg(-1). min(-1) (type 2 diabetic patients). Hypertension, hyperlipidemia, drug treatment with statins, ACE inhibitors, or nitrates had no effect on sGC activity. In conclusion, the present findings do not support the hypothesis that desensitization of sGC contributes to the pathogenesis of diabetic vascular dysfunction in humans.
Subject(s)
Diabetes Mellitus, Type 2/enzymology , Diabetic Angiopathies/epidemiology , Guanylate Cyclase/metabolism , Mammary Arteries/enzymology , Nitric Oxide/pharmacology , Aged , Coronary Disease/enzymology , Coronary Disease/epidemiology , Cyclic GMP/metabolism , Diabetic Angiopathies/enzymology , Female , Humans , Hydrazines/pharmacology , Male , Middle Aged , Nitric Oxide Donors/pharmacology , Nitrogen Oxides , Ventricular Dysfunction, Left/enzymology , Ventricular Dysfunction, Left/epidemiologyABSTRACT
A deterioration of renal function is one preoccupying complication of iodinated radiocontrast agents in clinical practice. These compounds have direct toxic effects on renal cells, which are only in part related to their physicochemical properties. The hyperosmolal monomeric ionic radiocontrast agents, like diatrizoate, have the highest toxicity, whereas renal cells are less affected by (nonionic) compounds with reduced osmolality. The toxic effects include cellular energy failure, a disruption of calcium homeostasis, a disturbance of tubular cell polarity and programmed cell death (apoptosis). The molecular mechanisms of the direct cytotoxicity are still unclear, although oxidative stress has been implicated. Radiocontrast cytotoxicity has been demonstrated in glomerular mesangial cells and in renal epithelial cells in vitro. In vivo, the direct cellular toxicity of radiocontrast agents is compounded with alterations in blood flow and/or viscosity, ultimately resulting in renal medullary hypoxia, which is a hallmark feature of the complex clinical syndrome of radiocontrast nephropathy.
Subject(s)
Acute Kidney Injury/chemically induced , Contrast Media/toxicity , Iodine Compounds/toxicity , Kidney/drug effects , Acute Kidney Injury/prevention & control , Animals , Cell Line , Kidney/cytology , Kidney Tubules/cytology , Kidney Tubules/drug effectsABSTRACT
BACKGROUND: Mutations in the human SLC4A1 (AE1/band 3) gene are associated with hereditary spherocytic anaemia and with distal renal tubular acidosis (dRTA). The molecular diagnosis of AE1 mutations has been complicated by the absence of highly polymorphic genetic markers, and the pathogenic mechanisms of some dRTA-associated AE1 mutations remain unclear. Here, we characterized a polymorphic dinucleotide repeat close to the human AE1 gene and performed an immunocytochemical study of kidney tissue from a patient with inherited dRTA with a defined AE1 mutation. METHODS: One CA repeat region was identified in a phage P1-derived artificial chromosome (PAC) clone containing most of the human AE1 gene and the upstream flanking region. We determined its heterozygosity value in multiple populations by PCR analysis. Genotyping of one family with dominant dRTA identified the AE1 R589H mutation, and family member genotypes were compared with the CA repeat length. AE1 and vH(+)-ATPase polypeptides in kidney tissue from an AE1 R589H patient were examined by immunocytochemistry for the first time. RESULTS: This CA repeat, previously reported as D17S1183, is approximately 90 kb upstream of the AE1 gene and displayed considerable length polymorphism, with small racial differences, and a heterozygosity value of 0.56. The allele-specific length of this repeat confirmed co-segregation of the AE1 R589H mutation with the disease phenotype in a family with dominant dRTA. Immunostaining of the kidney cortex from one affected member with superimposed chronic pyelonephritis revealed vH(+)-ATPase-positive intercalated cells in which AE1 was undetectable, and proximal tubular epithelial cells with apparently enhanced apical vH(+)-ATPase staining. CONCLUSIONS: The highly polymorphic dinucleotide repeat adjacent to the human AE1 gene may be useful for future studies of disease association and haplotype analysis. Intercalated cells persist in the end-stage kidney of a patient with familial autosomal dominant dRTA associated with the AE1 R589H mutation. The absence of detectable AE1 polypeptide in those intercalated cells supports the genetic prediction that the AE1 R589H mutation indeed causes dominant dRTA.
Subject(s)
Acidosis, Renal Tubular/genetics , Acidosis, Renal Tubular/pathology , Anion Exchange Protein 1, Erythrocyte/genetics , Genetic Predisposition to Disease , Mutation , Polymorphism, Genetic , Acidosis, Renal Tubular/epidemiology , Case-Control Studies , Cohort Studies , Female , Gene Expression Regulation , Genes, Dominant , Genetic Markers/genetics , Genetic Testing , Humans , Incidence , Male , Pedigree , Reference Values , Sensitivity and SpecificityABSTRACT
We occluded a large arterial duct in a patient with atrial fibrillation, using an Amplatzer duct occluder, with no residual shunt at the end of the procedure. Follow-up revealed recanalization, which was successfully treated with a 4 mm Amplatzer ASD occluder. It is speculated the reopening of the initially occluded duct was the consequence of anticoagulation needed because of the atrial fibrillation.
Subject(s)
Atrial Fibrillation/complications , Balloon Occlusion , Ductus Arteriosus, Patent/therapy , Aged , Balloon Occlusion/instrumentation , Ductus Arteriosus, Patent/complications , Humans , MaleABSTRACT
Renal artery stenosis most often is caused by atherosclerosis. Although patients with renal artery stenosis can be managed conservatively, renal revascularization may be indicated, particularly in patients with refractory hypertension on a multidrug regimen and patients with declining renal function. Duplex ultrasonography of the renal arteries and magnetic resonance angiography are currently the most efficient noninvasive methods for the evaluation of renal artery stenosis. Selective digital subtraction renal arteriography remains the gold standard for the definitive diagnosis. In selected patients undergoing coronary studies and angiography immediately after the coronary procedure can be efficient. Atherosclerotic renal artery lesions, which commonly affect the renal artery ostium, can be treated safely and effectively with balloon-expandable stents. Successful angioplasty commonly results in improved control of hypertension, but an overall benefit on renal function and/or patient survival has not been shown. Generally the risk/benefit ratio of renal artery stenting seems favorable, but further randomized studies are needed for evidence-based decision making. All patients with atherosclerotic renal artery stenosis should receive rigorous secondary prevention measures including platelet inhibitors, statins, and beta-blockers.
Subject(s)
Arteriosclerosis/complications , Renal Artery Obstruction/diagnosis , Renal Artery Obstruction/therapy , Angioplasty, Balloon, Coronary , Humans , Renal Artery Obstruction/etiology , Treatment OutcomeABSTRACT
Vascular endothelial growth factor (VEGF) induces increased vessel permeability and formation of abnormal vessels. To investigate cerebral blood flow (CBF) during local overexpression of VEGF recombinant adenoviruses carrying the human VEGF165 complementary DNA (2.3 to 23. 108 pfu/mL) were injected stereotactically into the caudate nucleus of anesthetized rats. Saline and adenoviruses carrying the beta-galactosidase gene served as controls. Eleven days later (1) size and density of vessels were assessed in hematoxylin-eosin-stained sections, (2) vascular permeability was measured by intravenous Evans blue injections, and (3) local CBF (lCBF) was quantified using the iodo-[14C]antipyrine technique. Dose-dependent increases were found in (1) vessel density and size (only vessels >43 microm could be quantified morphologically), (2) Evans blue extravasation and brain edema formation, and (3) lCBF (up to eightfold). At medium doses, hyperemic areas and smaller areas of decreased lCBF were found. In low flow areas, vascular cross-sectional areas were increased 223-fold and vessel density up to 10-fold. In high flow areas, these parameters were increased 32-fold and up to 15-fold, respectively. Adenovirus mediated VEGF overexpression results in (1) increased vessel size and density, (2) areas of increased and of decreased flow, and (3) more and smaller vessels in high flow than in low flow areas. These results indicate a diverging flow pattern of newly formed vessels.
Subject(s)
Adenoviridae/genetics , Blood-Brain Barrier/physiology , Cerebrovascular Circulation/physiology , Endothelial Growth Factors/genetics , Genetic Vectors , Intercellular Signaling Peptides and Proteins/genetics , Lymphokines/genetics , Animals , Brain Edema/physiopathology , Carbon Radioisotopes , Gene Expression , Humans , Male , Neovascularization, Physiologic/physiology , Rats , Rats, Wistar , Vascular Endothelial Growth Factor A , Vascular Endothelial Growth FactorsABSTRACT
RATIONALE AND OBJECTIVES: Radiocontrast-induced nephropathy (RCIN) is a major complication of intravascular radiocontrast administration. Renal tubular cell apoptosis is a feature of RCIN, which is related to hypertonicity of contrast agents. Because a hyperosmolal extracellular environment induces oxidative stress via reactive oxygen species, we tested the hypothesis that antioxidants decrease hypertonicity-induced apoptosis of renal epithelial cells. We analyzed the effects of the antioxidants N-acetylcysteine (NAC) and taurine on hypertonicity-induced apoptosis of renal epithelial cells in vitro. METHODS: Madin Darby Canine Kidney (MDCK) cells were incubated with the highly hyperosmolal, ionic radiocontrast agent diatrizoate (20% vol/vol, 6 hours) or with equally hyperosmolal (640 mOsm/kg) NaCl solutions. DNA fragmentation, which is a hallmark feature of apoptosis, was assessed quantitatively using flow cytometry after propidium iodide staining and qualitatively using agarose gel electrophoresis. RESULTS: Both diatrizoate and NaCl induced DNA fragmentation in MDCK cells. Taurine (10 mmol/L) reduced DNA degradation in both diatrizoate- [79.5 +/- 2.3% versus 72.2 +/- 3.0%; P = 0.0088] and NaCl- [49.5 +/- 4.0% versus 39.4 +/- 1.0%; P = 0.0271] treated cells. In contrast, NAC (10 mmol/L) failed to reduce the DNA breakdown in this model of hypertonicity-induced renal tubular cell apoptosis. CONCLUSIONS: The radiocontrast/hypertonicity-induced DNA fragmentation of MDCK cells is attenuated by taurine but not by NAC. Because both agents are antioxidants, the antioxidant property is not sufficient for the observed cytoprotective effect. Hence, the antiapoptotic effect of taurine has to be attributed to other, yet to be defined mechanisms. Our results suggest that pharmacological doses of taurine may be particularly protective against RCIN.
Subject(s)
Apoptosis , Contrast Media , Kidney Tubules/drug effects , Acetylcysteine/pharmacology , Animals , Cell Line , DNA Fragmentation , Diatrizoate/pharmacology , Dogs , Flow Cytometry , In Vitro Techniques , Kidney Tubules/pathology , Osmolar Concentration , Oxidative Stress , Sodium Chloride/pharmacology , Taurine/pharmacologyABSTRACT
Direct cytotoxic effects of radiocontrast (RC) agents have been implicated in radiocontrast nephropathy (RCIN). The interaction between extracellular calcium, which plays a central role in intercellular contacts, and the in vitro toxicity of RC was tested in Madin-Darby canine kidney (MDCK) cell monolayers grown on permeable supports. Cell viability was determined by trypan blue exclusion. The function of intercellular junctions was assessed by measuring the electrical transmonolayer resistance (TMR). The cell contacts were examined with indirect immunofluorescence microscopy using antibodies against the junctional proteins E-cadherin, ZO-1 and occludin. The ionic RC agents diatrizoate and ioxaglate (74 mg iodine/ml), but not the nonionic compounds iohexol or iodixanol, decreased ionized calcium (Ca2+) in the incubation media from 1.48 +/- 0.04 mM (control) to 0.89 +/- 0.06 mM (diatrizoate), respectively to 1.05 +/- 0.08 mM (ioxaglate). Diatrizoate, and to a lesser extent ioxaglate, reduced the number of viable MDCK cells and showed a redistribution of the E-cadherin, ZO-1 and occludin immunofluorescence signal with a parallel decrease of the TMR indicating an impaired monolayer integrity. A similar reduction of extracellular Ca2+ through EGTA failed to reproduce these effects. Conversely, raising Ca2+ in diatrizoate-containing media to control levels did not abrogate its toxicity. In conclusion, the ionic RC agents diatrizoate and ioxaglate, but not the nonionic compounds iohexol or iodixanol, reduce extracellular Ca2+ in vitro. However, this reduction of Ca2+ does not explain their cytotoxic effects which could contribute to the pathogenesis of RCIN in vivo by opening intercellular junctions.